Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Investigational medications adjunct to clinical standard of care treatment will be assessed
to evaluate safety and effectiveness as an anti-COVID-19 treatment. All hospitalized persons
with moderate to severe COVID-19 disease that meet eligibility criteria will be offered
participation.